NICE ruling on abiraterone

Posted 15th August 2014

The National institute of Clinical Excellence (NICE) has today announced its decision to not routinely fund the use of abiraterone for advanced prostate cancer patients who have not yet received first line chemotherapy treatment.

However, funding for patients who are eligible to receive abiraterone before chemotherapy is still available via the national Cancer Drug Fund. For patients receiving pre-chemotherapy abiraterone via the Cancer Drug Fund - your treatment will not be affected by this announcement.

Abiraterone will also continue to be routinely prescribed to advanced prostate cancer patients who have already had first line chemotherapy treatment, therefore we would like to reassure patients who are currently receiving this medicine after chemotherapy that their treatment will also not be affected by the announcement.

If you still have concerns please call 0151 482 7927